Linden Advisors’s Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share IBER.WS Stock Holding History

Linden Advisors’s Portfolio IBER.WS Stock Details IBER.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-192,734	Closed	-$2.1K	–	565
2022 Q4	$2.1K	Hold	192,734	–	–	﹤0.01%	561
2022 Q3	$19K	Hold	192,734	–	–	﹤0.01%	595
2022 Q2	$15K	Hold	192,734	–	–	﹤0.01%	685
2022 Q1	$35K	Sell	192,734 -32,265	-14%	-$9.69K	﹤0.01%	688
2021 Q4	$120K	Hold	224,999	–	–	﹤0.01%	700
2021 Q3	$130K	Hold	224,999	–	–	﹤0.01%	621
2021 Q2	$169K	Buy	+224,999	New	+$137K	﹤0.01%	708

Other funds holding IBER.WS

LCM

Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return

Linden Advisors's IBER.WS Position: Q1 2023 in Review

Linden Advisors sold out of Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share (IBER.WS) in Q1 2023, closing a stake of 192,734 shares — an estimated $2.1K sold.

Linden Advisors first reported a position in IBER.WS in Q2 2021 and held it in 7 quarters. The position peaked at $169K in Q2 2021. 1 fund tracked by Wall St. Rank holds IBER.WS as of Q1 2023.

Linden Advisors reported no remaining Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share position as of Q1 2023 after selling out during the quarter.
Linden Advisors sold 192,734 Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share shares in Q1 2023, an estimated $2.1K.
Linden Advisors first reported a position in Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share in Q2 2021 and held it in 7 quarters.
Linden Advisors's Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share position peaked at $169K in Q2 2021.
1 fund tracked by Wall St. Rank held Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share as of Q1 2023.

Based on Linden Advisors's 13F filing for Q1 2023, filed 15 May 2023.